Friday, January 24, 2025, San Francisco, California, 6:00 PM – 8:00 PM Pacific Time (9:00 PM – 11:00 PM Eastern Time)

What Clinicians Want to Know: Biomarker Assessment and Related Treatment Decision-Making for Patients with Colorectal Cancer

A CME Symposium Held in Conjunction with the 2025 ASCO® Gastrointestinal Cancers Symposium

Register for in-person Register for webcast

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, California
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
5:45 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Educational Dinner Meeting

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Arvind Dasari, MD, MS
Professor
Department of Gastrointestinal Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Van K Morris, MD
Associate Professor
Department of Gastrointestinal Medical Oncology Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jenny Seligmann, MBChB, MRCP, PhD
Professor of Gastrointestinal and Translational Oncology
Honorary Consultant Medical Oncologist
Division of Cancer Studies and Pathology
University of Leeds
Leeds, United Kingdom


Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospitals Leuven
Leuven, Belgium

Moderator
Christopher Lieu, MD
Professor of Medicine
Associate Director for Clinical Research
Co-Director, GI Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado



This activity is supported by educational grants from GSK, Natera Inc, and Pfizer Inc.
Program Schedule — Pacific Time
5:45 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Educational Dinner Meeting

Topics to Be Discussed

  • MODULE 1: Optimizing Biomarker Assessment for Patients with Colorectal Cancer (CRC)
  • MODULE 2: Incorporation of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient CRC
  • MODULE 3: Integration of Therapies Targeting HER2 in Metastatic CRC (mCRC)
  • MODULE 4: Biomarker-Based Decision-Making for Patients with mCRC and KRAS G12C Mutations
  • MODULE 5: Identification and Management of mCRC with a BRAF V600E Mutation

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Develop an understanding of validated biomarkers of response (eg, RAS mutations, microsatellite instability/mismatch repair deficiency [MSI/dMMR], HER2 overexpression, BRAF V600E mutations) found in patients with colorectal cancer (CRC) and consider the implications for molecular testing and clinical care.
  • Optimize the use of neoadjuvant and adjuvant systemic therapy for patients with localized CRC, considering the influence of various clinical and biological factors (eg, age, performance status, stage, MSI-high [MSI-H]/dMMR status) and the potential relevance of molecular residual disease.
  • Formulate a plan to guide the selection and sequencing of therapies for metastatic CRC (mCRC) accounting for the patient’s tumor sidedness, biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
  • Evaluate the biological rationale for the use of immune checkpoint inhibitors for MSI-H/dMMR localized and advanced CRC and counsel patients regarding evidence-based and guideline-endorsed treatment recommendations.
  • Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into the care of appropriate individuals.
  • Recognize available data with the use of HER2-targeted therapies for patients with HER2-positive mCRC, and consider the current role of FDA-approved approaches.
  • Apply available research to optimize the selection and sequencing of therapy for patients with mCRC and a KRAS G12C mutation considering the implications of recent clinical trial findings and regulatory actions.
  • Recall ongoing trials evaluating novel biomarker-directed agents and strategies for patients with CRC, and use this information to refer appropriate patients for study participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Dasari — Consulting Agreements: Bristol Myers Squibb, Exelixis Inc, Illumina, Lantheus, Personalis, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Eisai Inc, Enterome, Guardant Health, Hutchison MediPharma, Natera Inc, NeoGenomics, Personalis, Taiho Oncology Inc, Xencor. Prof Van Cutsem — Advisory Committees: AbbVie Inc, Agenus Inc, ALX Oncology, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cantargia AB (CANFOUR trial), Daiichi Sankyo Inc, Debiopharm, Eisai Inc, ElmediX, Galapagos NV, GSK, Hookipa Pharma Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Mirati Therapeutics Inc, MSD, Nordic Pharma, Novartis, Pfizer Inc, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Simcere, Taiho Oncology Inc, Takeda Pharmaceutical Company Limited, Terumo Medical Corporation; Nonrelevant Financial Relationship: Bexon Clinical Consulting.

MODERATOR — Dr Lieu — No relevant conflicts of interest to disclose.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from GSK, Natera Inc, and Pfizer Inc.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2025 ASCO® Gastrointestinal Cancers Symposium is taking place.

 
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.

There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2025 ASCO Gastrointestinal Cancers Symposium.

IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

Not an official event of the 2025 ASCO® Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.